The permeation of amphoteric drugs through artificial membranes - An in combo absorption model based on paracellular and transmembrane permeability

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 392-401

  Tam, Kin Y ^a   Avdeef, Alex ^b   Tsinman, Oksana ^b   Sun, Na ^b  

^a ASTRAZENECA   (United Kingdom)

^b PION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOLYTE; BENAZEPRIL; CARNITINE; CEFTAZIDIME; CERIVASTATIN; CETIRIZINE; CHLORTETRACYCLINE; CIPROFLOXACIN; DAUNORUBICIN; DEMECLOCYCLINE; ENOXACIN; FAMOTIDINE; FEXOFENADINE; GANCICLOVIR; GATIFLOXACIN; LISINOPRIL; LOMEFLOXACIN; MECILLINAM; MELOXICAM; MELPHALAN; MESALAZINE; MINOCYCLINE; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIROXICAM; SPARFLOXACIN; SULFADIAZINE; UNINDEXED DRUG;

ARTICLE; ARTIFICIAL MEMBRANE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT;

CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANES, ARTIFICIAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS;

EID: 74849106108     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901421c     Document Type: Article

References (59)

1. Pagliara, A.; Carrupt, P. A.; Caron, G.; Gaillard, P.; Testa, B. Lipophilicity profiles of ampholytes. Chem. Rev. 1997, 97, 3385-3400.
2. WHO Expert Committee. The Use of Essential Drugs; WHO: Geneva, 1995.
3. Ings, R. M. J. Pharmacokinetics. In Medicinal Chemistry: Principles and Practice; King, F. D., Ed.; RSC: Cambridge, 1994 pp 67-85.
4. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: highlights and hang-ups. J. Med. Chem. 2006, 49, 5029-5046.
5. Breedveld, P.; Beijnen, J. H.; Schellens, H. M. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 2006, 27, 17-24.
6. Petzinger, E.; Geyer, J. Drug transporters in pharmacokinetics. Naunyn-Schmeideberg's Arch. Pharmacol. 2006, 372, 465-475.
7. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes. J. Med. Chem. 1998, 41, 1007-1010.
8. Avdeef, A. Absorption and Drug Development; Wiley-Intercience: New York, 2003.
9. Wohnsland, F.; Faller, B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 2001, 44, 923-930.
10. Nielsen, P.; Avdeef, A. PAMPA-A Drug Absorption in vitro Model. 8. Apparent Filter Porosity and the Unstirred Water Layer. Eur. J. Pharm. Sci. 2004, 22, 33-41.
11. Avdeef, A.; Tsinman, O. PAMPA - a drug absorption in vitro model. 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DS-PAMPA. Eur. J. Pharm. Sci. 2006, 28, 43-50.
12. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPA - a useful tool in drug discovery. J. Pharm. Sci. 2007, 96, 2893-2909.
13. Avdeef, A.; Kansy, M.; Bendels, S.; Tsinman, K. Absorption-excipient-pH classification gradient maps: sparingly-soluble drugs and the pH partition hypothesis. Eur. J. Pharm. Sci. 2008, 33, 29-41.
14. Avdeef, A.; Bucher, J. J. Accurate measurements of the concentration of hydrogen ions with a glass electrode: calibrations using the Prideaux and other universal buffer solutions and a computer-controlled automatic titrator. Anal. Chem. 1978, 50, 2137-2142.
15. Sugano, K.; Takata, N.; Machida, M.; Saitoh, K.; Terada, K. Prediction of passive intestinal absorption using biomimetic artificial membrane permeation assay and the paracellular pathway model. Int. J. Pharm. 2002, 241, 241-251.
16. Saitoh, R.; Sugano, K.; Takata, N.; Tachibana, T.; Higashida, A.; Nabuchi, Y.; Aso, Y. Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of dose fraction of hydrophilic drugs absorbed by humans. Pharm. Res. 2004, 21, 749-755.
17. Sugano, K. Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population. Int. J. Pharm. 2009, 373, 55-61.
18. Adson, A.; Raub, T. J.; Burton, P. S.; Barsuhn, C. L.; Hilgers, A. R.; Audus, K. L.; Ho, N. F. H. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J. Pharm. Sci. 1994, 83, 1529-1536.
19. Reynolds, D. P.; Lanevskij, K.; Japertas, P.; Didziapetris, R.; Petrauskas, A. Ionization-specific analysis of human intestinal absorption. J. Pharm. Sci. 2009, 98, 4039-4054.
20. Ho, N. F. H.; Raub, T. J.; Burton, P. S.; Barsuhn, C. L.; Adson, A.; Audus, K. L.; Borchardt, R. Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers. In Transport Processes in Pharmaceutical Systems; Amidon, G. L., Lee, P. I., Topp, E. M., Eds.; Marcel Dekker: New York, 2000; pp 219-316.
21. flux method. Eur. J. Pharm. Sci. 2006, 24, 333-349.
22. Avdeef, A. Leakiness and Size Exclusion of Paracellular Channels in Cultured Epithelial Cell Monolayers - Interlaboratory Comparison. Unpublished results.
23. Winne, D. Dependence of intestinal absorption in vivo on the unstirred layer. Nauyn-Schmiedeberg's Arch. Pharmacol. 1978, 304, 175-181.
24. Yu, L. X.; Amidon, G. L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 1999, 186, 119-125.
25. Predicted values using Pharma Algorithms ADME Boxes Rev. 4.9.
26. 1-receptor antagonist. J. Med. Chem. 1998, 41, 853-863.
27. Leeson, L. J.; Krueger, J. E.; Nash, R. A. Concering the structural assigment of the second and third acidity constants of the tetracycline antibiotics. Tetrahedron Lett. 1963, 18, 1155-1160.
28. Bermejo, M.; Avdeef, A.; Ruiz, A.; Nalda, R.; Ruell, J. A.; Tsinman, O.; González, I.; Fernández, C.; Sánchez, G.; Garrigues, T. M.; Merino, V. PAMPA - a drug absorption in vitro model. 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 2004, 21, 429-441.
29. Ross, D. L.; Riley, C. M. Physicochemical properties of the fluoroquinolone antimicrobials. II. Acid ionization constants and their relationship to structure. Int. J. Pharm. 1982, 83, 267-272.
30. Omari, M. M. A.; Zughui, M. B.; Davies, J. E. D.; Badwan, A. A. Thermodynamic enthalpy-entropy compensation effects observed in the complexation of basic drug substrates with β-cyclodextrin. J. Inclusion Phenom. Macrocyclic Chem. 2007, 57, 379-384.
31. Ooie, T.; Suzuki, H.; Terasaki, T.; Sugiyama, Y. Comparative Distribution of Quinolone Antibiotics in Cerebrospinal Fluid and Brain in Rats and Dogs. J. Pharmacol. Exp. Ther. 1996, 278, 590-596.
32. Yalkowsky, S. H.; Zografi, G. Potentiometric Titration of Monomeric and Micellar Acylcarnitines. J. Pharm. Sci. 1970, 59, 798-802.
33. Takács-Novák, K.; Noszál, B.; Hermecz, I.; Keresztúri, G.; Podányi, B.; Szász, G. Protonation Equilibria of Quinolone Antibacterials. J. Pharm. Sci. 1990, 79, 1023-1028.
34. as of meloxicam on complexation with natural and modified cyclodextrins. Pharmazie 2007, 62, 55-59.
35. Fallab, S; Vögtli, W; Blumer, M Erlenmeyer. Zur Kenntnis. der p-aminosalicylsäure. Helv. Chim. Acta 1951, 34, 26-27.
36. Takács-Novák, K.; Tam, K. Y. Multiwavelength spectrophotometric determination of acid dissociation constants. Part V: Microconstants and tautomeric ratios of diprotic amphoteric drugs. J. Pharm. Biomed. Anal. 2000, 12, 1171-1182.
37. Takács-Novák, K.; Noszál, B.; Tokeskovesdi, M.; Szász, G. Acid - base properties of terbutaline in terms of protonation macro- and microconstants. J. Pharm. Pharmacol. 1995, 47, 431-435.
38. Wouters, J.; Michaux, C.; Durant, F.; Dogné, J. M.; Delarge, J.; Masereel, B. Isoterism among analogues of torsemide: conformational, electronic and lipophilic properties. Eur. J. Med. Chem. 2000, 35, 923-930.
39. Dollery, C. T. Therapeutic Drugs, 2nd ed.; Churchill Livingstone: New York, 1999.
40. FDA Drug Information (http://www.fda.gov/Drugs/default.htm).
41. Whomsley, R.; Benedetti, M. S. Development of new H1 antihistamines: the importance of pharmacokinetics in the evaluation of safe and therapeutically effective agents. Curr. Med. Chem. - Anti-Inflammatory Anti-Allergy Agents 2005, 4, 451-464.
42. Agwuh, K. N.; MacGowan, A. Pharmacokinetics and pharmcodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 2006, 58, 256-265.
43. Sietsema, W. K. The Absolute Oral Bioavailability of Selected Drugs. Int. J. Clin. Pharmcol. Ther. Toxicol. 1989, 27, 179-211.
44. Hinderling, P. H. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data. Biopharm. Drug Dispos. 2003, 24, 1-6.
45. Physician's Desk Reference, 63rd ed.; Thomson Reuters: Montvale, NJ, 2009.
46. Frydman, A. M.; Leroux, Y.; Lefebvre, M. A.; Djebbar, F.; Fourtillan, J. B.; Gaillot, J. Pharmacokinetics of Pefloxacin after Repeated Intravenous and Oral-Administration (400 mg bid) in Young Healthy Volunteers. J. Antimicrob. Chemother. 1986, 17 (Suppl. B), 65-79.
47. Teng, R.; Dogolo, L. C.; Willavize, S. A.; Friedman, H. L.; Vincent, J. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J. Antimicrob. Chemother. 1997, 39 (Suppl. B), 87-92.
48. Daniel, H.; Neugerbauer, B.; Kratz, A.; Rehner, G. Localization of acid microclimate along intestinal villi of rat jejunum. Am. J. Physiol. 1985, 248, G293-G298.
49. Lennernäs, H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007, 37, 1015-1051.
50. Petri, N.; Tannergren, C.; Rungstad, D.; Lennernäs, H. Transport characteristics of fexofenadine in the caco-2 cell model. Pharm. Res. 2004, 21, 1398-1404.
51. Tannergren, C.; Petri, N.; Knutson, L.; Hedeland, M.; Bondesson, U.; Lennernäs, H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 2003, 74, 423-436.
52. European Microdosing AMS Partnership Programme. Linear pharmacokinetics demonstrated between a microdose and therapeutic dose of the Pgp substrate in humans. In American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, 2008.
53. Lappin, G.; Stevens, L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 2008, 4, 1021-1033.
54. Obach, R. S.; Lombardo, F.; Waters, N. J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 2008, 36, 1385-1405.
55. del Amo, E. M.; Urtti, A.; Yliperttula, M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur. J. Pharm. Sci. 2008, 34, 161-174.
56. Kaiser, G.; Ackermann, R.; Brechbühler, S.; Dieterle, W. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril · HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharm. Drug Dispos. 1989, 10, 365-376.
57. Motohashi, H.; Uwai, Y.; Hiramoto, K.; Okuda, M.; Inui, K.-I. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol. 2004, 503, 25-30.
58. Dahan, A.; Amidon, G. L. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol. Pharmaceutics 2009, 6, 19-28.
59. Escher, B. I.; Berger, C.; Bramaz, N.; Kwon, J. H.; Richter, M.; Tsinman, O.; Avdeef, A. Membrane-water partitioning, membrane permeability and nontarget modes of action in aquatic organisms of the parasiticides ivermectin, ablendazole and morantel. Environ. Toxicol. Chem. 2008, 27, 909-918.